BioCardia, Inc. (BCDA) analyst actions
Rating and price-target actions on BCDA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BCDA overview →
3 measured BCDA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction | Press release | +0.00% | +0.44% | |
| BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study | Press release | +4.49% | -0.82% | |
| BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study | Press release | -0.52% | +1.80% |
Keep exploring
More BCDA: earnings → · SEC filings → · BCDA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AQUINOX PHARMACEUTICALS (AQXP) | 357 | 0.00% | 46% |
| Hologic, Inc. (HOLX) | 357 | -0.00% | 44% |
| BioMarin Pharmaceutical Inc. (BMRN) | 356 | -0.08% | 45% |
| McKesson Corporation (MCK) | 355 | +0.02% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.